Goldberg Richard M, Carrato Alfredo
Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC.
Gastrointest Cancer Res. 2008 May;2(3 Suppl):S19-24.
Overview of the Disease IncidencePrognosis Prognostic or Predictive FactorsCurrent General Therapy Standards and Regional Variations STANDARDS IN THE US AND EUROPE: Combination Therapy Plus a Biologic FOCUS and CAIRO 1: Serial Single Agents vs. Combination TherapyStop-and-Go StrategyLimited Availability of Biologics in Some RegionsAccomplishments During the Year TherapyWhat Needs To Be Done Controversies and Disagreements BOND-2 and PACCE: Chemotherapy + Bevacizumab + Cetuximab or PanitumumabSpecial Populations (Elderly and Poor Performance Status)Future Directions Comments on ResearchObstacles to Progress.
疾病发病率概述、预后、预后或预测因素、当前一般治疗标准及地区差异、美国和欧洲的标准:联合治疗加生物制剂、FOCUS和CAIRO 1:序贯单药治疗与联合治疗、停停走走策略、某些地区生物制剂供应有限、年度治疗成果、有待完成的事项、争议与分歧、BOND-2和PACCE:化疗+贝伐单抗+西妥昔单抗或帕尼单抗、特殊人群(老年人和体能状态差者)、未来方向、对研究的评论、进展障碍